Review



ar tic le in pr es s article  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress ar tic le in pr es s article
    Ar Tic Le In Pr Es S Article, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF-C%2C+Mouse%2FRat/pm42458244-125-0-20
    Average 94 stars, based on 1 article reviews
    ar tic le in pr es s article - by Bioz Stars, 2026-09
    94/100 stars

    Images



    Similar Products

    94
    MedChemExpress ar tic le in pr es s article
    Ar Tic Le In Pr Es S Article, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF-C%2C+Mouse%2FRat/pm42458244-125-0-20
    Average 94 stars, based on 1 article reviews
    ar tic le in pr es s article - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human vegf a
    Recombinant Human Vegf A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF-C%2C+Human/pm42236679-90-0-5
    Average 93 stars, based on 1 article reviews
    recombinant human vegf a - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    86
    Jingmei Biotech Co Ltd relevant parameters vegf c
    Relevant Parameters Vegf C, supplied by Jingmei Biotech Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/commercial+elisa+mouse/pm42156495-112-20-25
    Average 86 stars, based on 1 article reviews
    relevant parameters vegf c - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    MedChemExpress vegfc group
    Vegfc Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF-C%2C+Mouse%2FRat/10__3390_slash_ijms27104297-162-37-39
    Average 94 stars, based on 1 article reviews
    vegfc group - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress mouse recombinant vegfc
    Mouse Recombinant Vegfc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF-C%2C+Mouse%2FRat/pm42044813-65-13-16
    Average 94 stars, based on 1 article reviews
    mouse recombinant vegfc - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems vegfc
    Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/Recombinant+Human+VEGF-C+(Cys156Ser)+Protein/pm41944190-231-16-17
    Average 94 stars, based on 1 article reviews
    vegfc - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    97
    PromoCell vegf 165
    Vegf 165, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/Endothelial+Cell+Growth+Medium+2/pm41903119-261-5-11
    Average 97 stars, based on 1 article reviews
    vegf 165 - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    94
    Biosynth Carbosynth purified recombinant rat vegf c protein 152s
    VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
    Purified Recombinant Rat Vegf C Protein 152s, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vegf+c/VEGF+C+protein/pmc13012992-75-20-26
    Average 94 stars, based on 1 article reviews
    purified recombinant rat vegf c protein 152s - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice

    doi: 10.3389/fcvm.2026.1699372

    Figure Lengend Snippet: VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

    Article Snippet: Mice received intraperitoneal (IP) injections of VEGF-C (152s) at a dose of 50 ng per 25 g of body weight [purified recombinant rat VEGF-C protein (152s), Fitzgerald, catalog no. 30R-AV006-22] or vehicle control (phosphate-buffered saline, PBS), administered three times per week for four consecutive weeks.

    Techniques: Clinical Proteomics, Intravital Microscopy, Staining